Esophageal cancer (EC) is one of the most common and challenging types of cancer with 572,000 new diagnosis cases and 500,000 deaths annually. More than 50% of EC occur in East Asia, and 90% of those patients have esophageal squamous cell carcinoma (ESCC). Neoadjuvant therapy has been proved to improve the long-term survival of locally advanced esophageal cancer. The main neoadjuvant therapy types include neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT). However, the long-term survival in patients is still not promising. Due to this concern, immunotherapy has been introduced into neoadjuvant therapy for EC patients. Both neoadjuvant immunotherapy combined with nCT and neoadjuvant immunotherapy combined with nCRT showed a promising pathological complete response (pCR).
It’s crucial to further screen the beneficiaries of neoadjuvant therapy and develop individualized treatment plans for locally advanced EC. By identifying prognostic predictors and integrating these predictors properly, innovative scoring systems can be further developed to accurately assess the risk of adverse events, pathological response, survival, recurrence and metastasis in EC patients receiving neoadjuvant therapy.
The aim of this Research Topic is to identify emerging prognostic factors and predictive models that can be readily and objectively obtained before and after neoadjuvant therapy (especially immunotherapy) for EC patients, and to further refine the precise risk stratification of outcome. We welcome Original Research, Reviews, Mini Reviews, and Clinical Trials that explore the clinical significance of potential predictive tools related to peripheral blood detection, immunonutritional status, medical imaging, surgery, postoperative care, histology, or molecular characteristics of EC.
Esophageal cancer (EC) is one of the most common and challenging types of cancer with 572,000 new diagnosis cases and 500,000 deaths annually. More than 50% of EC occur in East Asia, and 90% of those patients have esophageal squamous cell carcinoma (ESCC). Neoadjuvant therapy has been proved to improve the long-term survival of locally advanced esophageal cancer. The main neoadjuvant therapy types include neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT). However, the long-term survival in patients is still not promising. Due to this concern, immunotherapy has been introduced into neoadjuvant therapy for EC patients. Both neoadjuvant immunotherapy combined with nCT and neoadjuvant immunotherapy combined with nCRT showed a promising pathological complete response (pCR).
It’s crucial to further screen the beneficiaries of neoadjuvant therapy and develop individualized treatment plans for locally advanced EC. By identifying prognostic predictors and integrating these predictors properly, innovative scoring systems can be further developed to accurately assess the risk of adverse events, pathological response, survival, recurrence and metastasis in EC patients receiving neoadjuvant therapy.
The aim of this Research Topic is to identify emerging prognostic factors and predictive models that can be readily and objectively obtained before and after neoadjuvant therapy (especially immunotherapy) for EC patients, and to further refine the precise risk stratification of outcome. We welcome Original Research, Reviews, Mini Reviews, and Clinical Trials that explore the clinical significance of potential predictive tools related to peripheral blood detection, immunonutritional status, medical imaging, surgery, postoperative care, histology, or molecular characteristics of EC.